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SUMMARY
Increasing evidence suggests Alzheimer’s disease (AD) pathophysiology is influenced by primary and sec-
ondary bile acids, the end product of cholesterol metabolism.We analyze 2,114 post-mortem brain transcrip-
tomes and identify genes in the alternative bile acid synthesis pathway to be expressed in the brain. A
targeted metabolomic analysis of primary and secondary bile acids measured from post-mortem brain
samples of 111 individuals supports these results. Our metabolic network analysis suggests that taurine
transport, bile acid synthesis, and cholesterol metabolism differ in AD and cognitively normal individuals.
We also identify putative transcription factors regulatingmetabolic genes and influencing alteredmetabolism
in AD. Intriguingly, some bile acids measured in brain tissue cannot be explained by the presence of enzymes
responsible for their synthesis, suggesting that they may originate from the gut microbiome and are trans-
ported to the brain. These findingsmotivate further research into bile acidmetabolism in AD to elucidate their
possible connection to cognitive decline.
INTRODUCTION
Alzheimer’s disease (AD), the leading cause of dementia, is a
progressive, multifactorial disease1,2 in which the onset and
progression of symptoms varies significantly among individuals.
Recent studies have shown that metabolic dysfunction is one of
the factors associated with neurodegenerative disorders.3,4
Various physiological processes such as lipid metabolism, im-
mune function, amyloid precursor protein metabolism, oxidative
stress, neurotransmitter function, and mitochondrial functions
are altered in AD, which can affect metabolism.5–7 Interest in
the transport of biochemical compounds between the brain
and the gut and their possible role in regulating metabolic
changes centrally and peripherally has increased recently across
several neurodegenerative diseases.8,9 There is increasing evi-
dence to suggest a role in AD for primary and secondary bile
acids (BAs).7,10,11 BAs are amphipathic molecules and primary
BAs are derived from cholesterol, mostly in the liver, whereas
secondary BAs are typically produced by bacteria in the gut.12
Increased levels of secondary BAs and ratios to their primary
BA educts have been linked to AD and cognitive decline.7
Cholesterol metabolism and transport have been studied
extensively and are clearly linked with AD.1,13,14 Cholesterol
clearance leads to the production of BAs that carry out lipid ab-
sorption and cholesterol homeostasis and also function as
signaling molecules.15 Primary BAs such as cholic acid (CA)
and chenodeoxycholic acid (CDCA) are synthesized as a result
of cholesterol efflux and then conjugated with glycine or taurine
for secretion into bile and later metabolized by gut bacteria.12
There are two major BA biosynthetic pathways: the classical
pathway (neutral pathway) and the alternative pathway (acidic
pathway). The classical pathway in mammalian liver is initiated
by cholesterol 7a-hydroxylase (CYP7A1) and subsequently
requires 12a-hydroxylase (CYP8B1), among numerous other
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enzymes, for the synthesis of CA, whereas CDCA is produced in
the absence of CYP8B1.16 Sterol 27-hydroxylase (CYP27A1)
is required for the initiation of an alternative BA pathway.17
In the brain, sterol 24-hydroxylase (CYP46A1) converts choles-
terol to 24S-hydroxycholesterol (systematic name cholest-5-
en-3b,24S-diol), and subsequently, 7a-hydroxylation is carried
out by 24-hydroxycholesterol 7a-hydroxylase (CYP39A1)18 (Fig-
ure 1). Studies in human andmouse brain samples, aswell as cell
lines, have shown that BAs can cross the blood-brain barrier
(BBB) and bind to nuclear receptors, causing physiological
changes.19,20 There is limited information on the role of BAs in
the human brain and their association with cognitive decline in
AD pathophysiology. Systematic analysis of omics data derived
from blood and post-mortem brain samples of AD and cogni-
tively normal (CN) or control individuals has the potential to iden-
tify differences in cholesterol and BA metabolism and how they
contribute to AD pathogenesis.
In this study, we analyzed a large number of transcriptome
data from the Religious Orders Study and Memory and Aging
Project (ROSMAP), the Mayo Clinic, and the Mount Sinai Brain
Bank that had a total of 2,114 post-mortem brain samples
from 7 different brain regions. We reconstructed metabolic net-
works using the data from these 3 cohorts and studied the role
of circulating BAs that may contribute to AD and altered choles-
terol metabolism in these individuals. We also generated tar-
geted metabolomics data of primary and secondary BAs from
the post-mortem brain samples of 111 AD patients and controls.
Various genomic studies have reported transcriptional regula-
tory changes in neurodegenerative diseases.21,22 The biological
significance of these transcription factors (TFs) regulating meta-
bolic changes is not completely understood. The brain-specific
metabolic and transcriptional regulatory networks proved useful
in identifying candidate metabolites and genes involved in the
disease manifestation. A schematic representation of the study
is represented in Figure 1. Our study used the following ap-
proaches to investigate the role of BAs in AD:
(1) Transcriptional profiling of genes that are involved in
cholesterol and BA metabolism using publicly available
data from post-mortem brain samples
(2) Reconstruction and analysis of genome-scale metabolic
networks of various brain regions to identify genes and re-
actions that are significant in AD versus CN
(3) Transcriptional regulatory network analysis of brain sam-
ples to predict candidate TFs regulating metabolically
important genes
Figure 1. Graphical Overview of Analyses Described Herein to Study Altered Cholesterol and Bile Acid (BA) Metabolism in AD
Numbers of samples from each brain region are indicated along with AD and control samples and male/female breakdown in parentheses. We used the
post-mortem brain sample transcriptome data to generate region-specific metabolic networks. We used these networks to study BA and cholesterol
metabolism. Using the brain transcriptional regulatory network, we identified transcription factors that regulate genes in cholesterol and BAmetabolism. See also
Table S1.




In summary, our study addresses an important need to better
understand the potential roles of BAs in AD pathophysiology.
RESULTS
In recent studies, cytotoxic and neuroprotective BAs were iden-
tified in AD and their probable link to cognitive decline in the
individuals was reported.7,23 To further investigate the role of pri-
mary and secondary BAs in AD and CN individuals, we analyzed
2,114 post-mortem brain samples from 3 independent cohorts
for 7 brain regions (Table S1) and selected genes involved in
cholesterol and BA metabolism.
Here, we studied the role of BAs in AD pathology in the context
of genome-scale metabolic and transcriptional regulatory net-
works (Figure 1).
Transcriptomic Analysis of Genes Encoding Enzymes
Associated with BA Metabolism
BAs are products of cholesterol metabolism. To identify choles-
terol and BA genes that are expressed in the brain, we curated a
list of regulators, transporters, and biosynthesis genes in these
three independent cohorts. Cholesterol biosynthesis regulators
SREBF1 and SREBF2 were expressed in post-mortem brain
samples, and recent studies have identified variants of SREBP2,
the protein encoded by SREBF2, and their probable link with
AD.14,24,25 The expression of genes involved in cholesterol trans-
port—ABCA1, ABCA5, ABCA7, APOE, LPL, and LCAT and
members of the low-density lipoprotein receptor (LDLR) gene
family (LDLR, VLDLR, LRP1, LRP2, LRP4, LRP5, LRP6, LRP8,
LRAD3) in the brain samples suggests the active transport of
cholesterol and cholesterol homeostasis in the brain (Figure 2).
ABCA7, a cholesterol transporter belonging to the class of
ATP-binding cassette transporters that has been identified as a
risk factor for late-onset AD,17 is not found in the existing Kyoto
Encyclopedia of Genes and Genomes (KEGG) pathways and
was manually curated into our models. ABCA7 was expressed
in the post-mortem brain samples. We also probed genes en-
coding for receptors linked with the classical and alternative
BA pathway and found expression of PPARA, PPARG, LXRa/
b, RAR, and RXRs (RXRA, RXRB, RXRG) in the samples but no
evidence of expression of the farnesoid X receptor/BA receptor
(FXR).
We observed the consistent expression of CYP27A1 and
CYP7B1, which are involved in the initial steps of the alternative
Figure 2. Transcriptomic Analysis of Genes Associated with Cholesterol and BA Metabolism
Heatmap of cholesterol (A) and BA metabolism (B) genes. The color gradient is based on ubiquity scores calculated for the genes and the gray color represents
genes having no expression data in the brain regions from the 3 cohorts. Brain regions represented in the plot are cerebellum (CER), prefrontal cortex (FC),
temporal cortex (TC), frontal pole (FP), inferior frontal gyrus (IFG), parahippocampal gyrus (PHG), and superior temporal gyrus (STG). The function of genes is
indicated on the left side of each heatmap.




BA pathway depicted in Figure 3, from the analysis of transcrip-
tomic data of post-mortem brain samples from three indepen-
dent cohorts (Table S1). In Figure 3, the BAs are marked as cyto-
toxic and neuroprotective,7,23 but all BAs become toxic at
elevated concentrations because of their ability to solubilize
membranes.23 We did not observe expressions of CYP7A1
and CYP8B1, suggesting that the classical BA biosynthesis
pathway is not prevalent in the brain samples. The classical
pathway is known to be most active in the liver.26 It has been re-
ported that neural cholesterol clearance through BA synthesis is
mediated by CYP46A1, and subsequently by CYP39A1 in the
liver, leading to the synthesis of CDCA.11,27 In addition to genes
involved in the alternative BA pathway, we also observed the
expression of brain-specific CYP46A1 and CYP39A1 genes in
all of the cohorts. This analysis suggested that the brain uses
an alternative and neural cholesterol clearance pathway of BA
synthesis11,27 and not the classical pathway.23
Metabolomics Analysis of Post-mortem Brain Samples
to Identify Levels of Primary and Secondary BAs
BAs were quantified from 111 post-mortem brain samples
from the dorsolateral prefrontal cortex of individuals with AD,
mild cognitive impairment (MCI), and CN in the ROSMAP study
(https://www.synapse.org/#!Synapse:syn10235594) (Table S2).
Although the genes involved in the production of CA were not
expressed in the brain samples, the detection of CA from theme-
tabolomics analysis suggested that CA may enter the brain from
the periphery, as previously shown in other studies.20,28,29 We
compared the levels of primary and secondary BAs in individuals
with a Consortium to Establish a Registry for Alzheimer’s
Disease (CERAD) score of 1–4, in which 1, 2, 3, and 4 indicate
definitive AD, probable AD, possible AD, and no evidence of
AD, respectively. The ratio of primary conjugated and secondary
BAswith respect to CA showed that deoxycholic acid (DCA), lith-
ocholic acid (LCA), glycochenodeoxycholate (GCDCA), CDCA,
taurodeoxycholic acid (TDCA), glycodeoxycholic acid (GDCA),
ursodeoxycholic acid (UDCA), allolithocholate (alloLCA) and
taurocholic acid (TCA) were higher in individualswith AD (CERAD
score 1–3) compared to controls (Figure 4). Similar results were
reported in the serum metabolomics samples of AD and CN in-
dividuals.7,10 Allo-cholic acid (ACA) is a steroid BA that has
been studied in the context of signaling mechanisms related to
differentiation, proliferation, or apoptosis of hepatocytes.30 The
CDCA:CA ratio was calculated, and it showed a higher value
Figure 3. Schematic Representation of BA Synthesis Pathway in Humans
Genes expressed in brain samples from our analysis are highlighted in pink. The order of enzymatic reactions can vary. Based on the results from Mahmou-
dianDehkordi et al.,7 BAs have been marked as neuroprotective or cytotoxic.




for AD compared to CN individuals in the study (Table S3). This
finding suggests that the alternative BA pathway is more active
in AD versus CN individuals. Also, the higher ratio of primary
BAs, like TCA, and secondary BAs, such as DCA, LCA, TDCA,
and GDCA, in AD individuals indicated that these BAs may be
associated with cognitive function.
The primary BAs are conjugated with glycine or taurine for
secretion into bile.17 In addition to the primary and secondary
BAs, we also measured levels of taurine in serum samples in
AD and CN individuals. In the serum, we observed that AD pa-
tients had higher levels of serum taurine compared to controls.
Taurine is required for the conjugation of primary and secondary
BAs. This is an interesting observation, and we need to explore
the transport and physiological levels of taurine in the brains of
individuals with AD.
Metabolic Reconstruction of Brain Regions and
Pathway-Level Analysis
We reconstructed metabolic networks for brain region-specific
samples in the three independent cohorts. The seven brain re-
gions in this study included cerebellum (CER), prefrontal cortex
(FC), temporal cortex (TC), frontal pole (FP), inferior frontal gyrus
(IFG), parahippocampal gyrus (PHG), and superior temporal gy-
rus (STG). We used transcriptome data from post-mortem brain
samples for reconstructing metabolic networks (see STAR
Methods for more details). The brain region-specific metabolic
networks consisted of 5,600–6,300 reactions, 2,800–4,000
metabolites, and each model had genes varying from 1,500 to
1,757 in these networks. Figure S1A provides information about
the numbers of reactions, metabolites, and genes present in
each of the brain region-specific networks, and Figure S1B com-
pares the gene content overlaps across each of these networks.
We have made the detailed content of all of these models avail-
able to the scientific community (Tables S4–S10).
We tested each model using 16 brain-specific in silico tests
meant to mimic the experimental evidence of metabolic func-
tions in the brain (‘‘metabolic tasks’’) (Table S11) that were
obtained from a recently published work on human reconstruc-
tion.31 These metabolic tasks represent a set of reactions that
are brain specific, and themetabolic networks generated passed
Figure 4. Metabolomics Analysis of Post-
mortem Brain Samples to Identify Levels of
Primary and Secondary BAs
Bar plots representing the ratio of BAs with respect
to cholic acid (CA) (primary BA) are shown here.
The primary and secondary BAs measured from
111 brain samples from the ROSMAP study are
represented here. The blue bars represent AD
samples and the light orange bars represent con-
trol samples. See also Table S3.
65%–85% of the tasks (see STAR
Methods). The metabolic tasks are listed
in Table S11 and the models are provided
in SBML in https://github.com/PriceLab/
Bile_acid_AD. In addition to generating
brain region-specific metabolic networks,
we also used the transcriptome data of 2,114 post-mortem brain
samples and obtained personalized networks for each sample in
the study. Of the 2,114 brain samples, 818 samples corre-
sponded to individuals with AD, 138 to possible AD, 137 to prob-
able AD, and 617 controls. The dataset also consisted of 12 sam-
ples from other dementias, 163 samples with progressive
supranuclear palsy, 58 samples with pathologic aging, and 2
samples that were uncharacterized. From our metabolic net-
works, we identified 518 reactions that were involved in choles-
terol metabolism, BA synthesis, and transport of BAs between
different compartments in the metabolic networks. The person-
alized metabolic networks had distinct sets of BA reactions
active in the brain regions (details in STAR Methods). Since the
post-mortem brain samples for the brain regions were collected
by three independent cohorts having different sequencing proto-
cols and depth, the flux results were analyzed separately for
these cohorts. The data suggest that the CER and TC have
similar sets of BA reactions that can be active in the personalized
metabolic networks (Figure 5).
We analyzed the reaction fluxes and found a similar set of BA
reactions carrying fluxes in metabolic networks of these inde-
pendent cohorts. We used this information to carry out statistical
analyses and identify reactions that are significantly different (p <
0.05) in brain regions of AD versus theCN individuals and to iden-
tify reactions that were significant in males versus females with
AD. We found that reactions carrying out the transport of taurine
and cholesterol were significant in the dorsolateral prefrontal
cortex, TC and PHG. Taurine is an abundant amino acid present
at roughly 1.2 mM in the brain.32 SLC6A6 (TAUT) and SLC36A1
(PAT1) function as taurine transporters, and increased transport
of taurine across the BBB has been reported for oxidative stress
conditions.33We found expressions of both of these genes in the
brain transcriptome dataset, suggesting that these genes are
expressed in the brain and involved in the transport of taurine.
Table 1 provides details for significant BA reactions in brain re-
gions identified from our analysis.
From our analysis, we identified reactions with CYP27A1,
required by the neural cholesterol clearance pathway, the clas-
sical pathway, and the alternative BA pathway, as being signifi-
cant in AD versus CN brains. Other than BA synthesis, reactions




involving metabolites such as 7a-hydroxycholesterol (Virtual
Metabolic Human [VMH], www.vmh.life, VMH: xol7a), 7a-hy-
droxy-5b-cholestan-3-one (VMH: xol7ah), 3a,7a-dihydroxy-
5b-cholestane (VMH: xol7ah2), and 7a-hydroxy-cholestene-3-
one (VMH: xol7aone) were also identified as being significantly
different between AD and CN (p values for these reactions re-
ported in Table 1). The transport of BAs such as taurolithocholic
acid 3-sulfate (VMH: HC02198), UDCA (VMH: HC02194), TCA
(VMH: tchola), and 3-dehydroxychenodeoxycholic acid (VMH:
3dhchchol) can also be probed further to understand the role
of these BAs in AD. Thus, in silico analysis of brain region-
specific metabolic networks provides insights into reactions
that may be involved inmetabolic changes in AD that can be vali-
dated from experimental data.
Identifying Transcriptional Regulators Responsible for
Altered Metabolism in AD
TFs are one important aspect of metabolic regulation that
operate by adjusting the expression of genes encoding en-
zymes. Using a transcriptional regulatory network informed
from the same Mayo TC bulk RNA-seq samples used for the
metabolic reconstruction, we identified candidate TFs that
interact with metabolic genes in cholesterol and BA meta-
bolism. We selectively studied those genes that belonged to
reactions that were significantly differentially expressed in AD
versus controls to study their role in AD. For example, one
gene that came up from our metabolic analysis of AD and con-
trols was emopamil-binding protein (EBP) (Figure 6). EBP is
involved in cholesterol metabolism, as it is responsible for one
of the final steps in the production of cholesterol. Our brain tran-
scriptional regulatory network (TRN) analysis identified
POU6F2, IRF2, SMAD5, GABPA, and TBR1 as the top candi-
date TF regulators for EBP. Regulation by these TFs can help
in understanding their role in altered cholesterol metabolism
in AD, particularly in evaluating the summation of coordinated
changes since these TFs control other genes as well.
CYP27A1, as mentioned earlier, is part of the alternative BA
synthesis pathway, and CREB3L2 and SOX8 are putative TFs
that regulate the expression of this gene. CREB3L2 (cyclic
AMP [cAMP]-responsive element binding protein 3-like 2) is
induced as a result of endoplasmic reticulum (ER) stress and
may function in unfolded protein response signaling in neu-
rons.34 Other than the metabolism-related genes, we also eval-
uated the interactions of BA transporters such as SLC6A6,
SLCO1A2, ABCC1, ABCA1, SLC36A1, and ABCA8 and their
transcriptional regulation. As seen in Figure 6, SREBF2 was
found to interact with ABCA1, and recently there were reports
of variants of SREBP2 that have been linked with AD.25
Increased SREBF2 expression leads to higher cholesterol
levels and presumably oxysterol and cholestenoic acid levels,
which are ligands of the liver X receptor (LXR). The peroxisome
proliferator-activated receptors (PPARs) regulate various phys-
iological processes and are expressed in the central nervous
system. PPARA regulates genes involved in fatty acid meta-
bolism and has been reported to regulate neuronal ADAM10
expression, in turn affecting the proteolysis of the amyloid pre-
cursor protein.35 PPARA was identified as a putative regulator
of ABCA1 in our brain transcriptional regulatory network.
ABCA1 plays a role in cholesterol metabolism and transport
and is a candidate risk gene for late-onset AD (LOAD).36
SLC6A6, involved in the transport of taurine, was found to
be putatively regulated by STAT1, a TF reported to play an
important role in spatial learning and memory formation,37
and RXRG, which forms heterodimers with retinoic acid (RA),
LXRs, and vitamin D receptors (VDRs).38 Neuronal differentia-
tion 6 (NEUROD6) functions in neuronal development, differen-
tiation, and survival in AD.39 The regulation of SLC36A1 by
NEUROD6 indicated that this TF plays a role in controlling the
transport of taurine in the brain. These interactions can be
probed further to understand their role in AD pathophysiology.
Figure 5. Metabolic Reconstruction of Brain Regions and Analysis of Reactions Involved in BA Metabolism
Clustergram for 518 reactions involved in BA metabolism.
(A) Mayo clinic cohort (CER and TC).
(B) ROSMAP cohort (FC).
(C) Mount Sinai Brain Bank (FP, IFG, STG, and PHG).
The rows correspond to BA reactions in the network and the columns are colored based on the brain regions.




In summary, the brain transcriptional regulatory network anal-
ysis led to the identification of candidate TFs that regulate genes
in cholesterol and BA metabolism, providing clues toward
possible roles in BA dysregulation in AD.
DISCUSSION
Wecarried out a systematic study to identify alterations in choles-
terol and BA metabolism in AD versus CN controls using patient-
derived post-mortem transcriptomics and metabolomics data.
The primary findings of our study are (1) alternative and neural
cholesterol clearance pathway of BA synthesis pathway genes
were expressed in the brain samples included in this study, indi-
cating that thesepathways are prevalent in the brain as compared
to the classical BA synthesis pathway; (2) targeted metabolomics
analysis of post-mortem brain samples identified primary and
secondary BAs and higher ratios of GCDCA:CA, and secondary
BAs such as DCA, LCA, TDCA, CDCA, and GDCA in AD versus
controls suggest that these BAsmay be associatedwith cognitive
decline in AD; (3) the presence of secondary BAs inmetabolomics
data suggests a possible role of the gut microbiome in AD and
highlights the need to study the gut-brain axis to understand
changes in AD; (4) transporters associated with taurine and
cholesterol metabolism showed different usage based on our
genome-scale metabolic network analysis of three independent
cohorts; and (5) transcriptional regulatory network analysis iden-
tified TFs, including PPARA, RXRG, and SREBF2, regulating BA
and cholesterol genes in the brain.
Role of BAs in AD Pathophysiology and Use of Genome-
Scale Metabolic Models
BAs are derived from cholesterol, and their synthesis is regulated
by complex feedback mechanisms.12,18 Recent studies have
identified BAs in brain samples and linked them with cognitive
decline in AD.7,10,19 To understand the physiological role of
BAs in the brain of AD and CN individuals, we analyzed transcrip-
tome data from post-mortem brain samples obtained from three
independent cohorts and identified that genes involved in the
alternative BA pathway were expressed compared to the clas-
sical pathway in the brain. The alternative BA pathway is initiated
by CYP27A1, which catalyzes the steroid side-chain oxidation
and in the subsequent step forms C24-BAs. It is also known
that cholesterol is converted to 24-hydroxycholesterol by
cholesterol 24-hydroxylase (CYP46A1) in the brain, and the
gene was found to be expressed in the brain samples. The pri-
mary BAs conjugate with glycine and taurine to form conjugated
BAs. Taurine plays a neuroprotective role in the brain, and BAs
conjugated with taurine are found to be present in the brain. Me-
tabolomics data of serum samples showed that AD patients had
higher levels of serum taurine compared to controls, indicating
that taurine transport across the BBB may be affected in AD.
The presence of secondary BAs in the post-mortem brain sam-
ples suggests that these BAs are either endogenously present in
the brain or they are transported through the BBB. BAs such as
UDCA, TCA, taurolithocholic acid 3-sulfate, and 3-dehydroche-
nodeoxycholic acid were also identified from our analysis, and
the role of these BAs can be probed further. Based on an asso-
ciation study, taurolithocholic acid was predicted to be a cyto-
toxic BA, whereas chenodeoxycholic acid and UDCA were
predicted to be neuroprotective BAs.7 Our analysis of the
transcriptome data of 2,114 samples mapped into the metabolic
networks of brain regions implicated reactions involved in the
production of metabolites such as 7a-hydroxycholesterol,
7a-hydroxy-5b-cholestan-3-one, 7a-hydroxycholestene-3-one,
and other derivatives that are formed through CYP7A1 being
significantly different (p values for these reactions reported in
Table 1) between AD and CN. Although CYP7A1 was not ex-
pressed in the post-mortem brain samples, the difference in
abundance of these metabolites in AD versus CN suggests
that we should explore the possibility of these metabolites
entering the brain through the periphery. Our brain-tissue meta-
bolic models can be used by the community to capture in silico
changes and possibly identify metabolic biomarkers ahead of
disease manifestation, making them useful in understanding
interactions and mechanisms between different classes of
metabolites and AD pathophysiology.
Table 1. List of Bile Acid (BA) Reactions from Our Metabolic




Associated Subsystem p Value
Frontal Cortex
AKR1C41 AKR1C4 BA synthesis 0.033
r2505 ABCC1 transport, endoplasmic
reticular
0.030
r2146 SLCO1A2 transport, extracellular 0.023
TAUBETAtc SLC6A6 transport, extracellular 0.009
Temporal Cortex





TAUPAT1c SLC36A1 transport, extracellular 0.0165




EBP1r EBP cholesterol metabolism 0.0433
HMGLx HMGCL cholesterol metabolism 0.0293
DHCR241r DHCR24 cholesterol metabolism 0.0413
EBP2r EBP cholesterol metabolism 0.0277
PHG




r1052 transport, lysosomal 0.047




TAUPAT1c SLC36A1 transport, extracellular 0.015
The reactions are represented in their VMH IDs, and information related to
the genes and subsystems are also shown in the table. p values calcu-
lated by Fisher’s exact test are indicated in the table, and only those
reactions with p < 0.05 are represented here.




Transcriptional Regulation of BA and Cholesterol Genes
Metabolism is influenced by the regulation of TFs and metabolic
genes. In this study, we used a transcriptional regulatory network
of brain (and selected brain regions) to identify candidate TFs
that may interact with genes in cholesterol and BA metabolism.
We identified SREBF2, PPARA, RXRG, and other TFs, some of
which have been studied and implicated in AD. SREBF2 expres-
sion enhances cholesterol levels40 and presumably oxysterol
and cholestenoic acid levels, which are ligands of LXR.41 LXRs
and the genes regulated by LXRs such as ABCA1, ABCG1,
and APOE, modulate intracellular cholesterol content and
cholesterol efflux and have been associated with AD pathogen-
esis.42 Our analysis also identified PPARA as a putative regulator
of ABCA1, and recent studies have demonstrated that PPAR
Figure 6. Transcriptional Regulators Responsible for Altered Cholesterol and BA Metabolism in AD
Transcriptional regulatory network of brain highlighting transcription factors (TFs) and metabolic genes involved in cholesterol and BA metabolism. TFs are
represented as blue triangles, BAmetabolism genes as yellow circles, and cholesterol metabolism genes as pink rectangles. The significant genes are highlighted
with a red border and TFs in a darker shade of blue. The red edges represent interactions between genes and TFs.




pathway activation increases ABCA1 levels, which in turn led to
APOE lipidation and amyloid b clearance.43 We also identified
the transport of taurine as an important factor from themetabolic
analysis. SLC6A6 (neurotransmitter transporter, taurine) and
SLC36A1 (neutral amino acid/proton symporter) play a role in
taurine transport. Although there was a 1.02- to 1.3-fold
change in the expression of these transporters in AD compared
with control samples of the three cohorts across four tested brain
regions, this difference was only found to be statistically signifi-
cant in CER (Table S1). The integration of expression data with
the metabolic networks of brain regions identified reactions
involving taurine transporters that were statistically significant
in AD versus controls, further supporting their potential role.
We had also identified STAT1 as a putative TF of SLC6A6 from
our analysis of brain regulatory networks. Studies have sug-
gested that the increased STAT1 may be involved in inflamma-
tion in the AD brain.37,44 NEUROD6 regulates the activity of
SLC36A1, a proton-coupled amino acid transporter. NEUROD6
is a basic helix-loop-helix TF, and SNPs in NEUROD6 have been
associated with AD, especially in APOE4+ women.45 Our anal-
ysis has been able to capture metabolic genes and putative
TFs that regulate them. These findings can be further strength-
ened by the generation of higher-quality footprint data from brain
samples.
Studying theGut-Brain Axis to Understand Physiological
Changes in AD
Increasing evidence from experimental and clinical data suggests
the influence of the gut-brain axis and gut microbiota in neurode-
generative diseases.46,47 From our metabolic analysis, we identi-
fied taurolithocholic, 3-dehydrochenodeoxycholic, and UDCA,
secondary BAs, that are significant in AD compared to CN,48 sug-
gesting a possible connection to the gut microbiome. Recently,
the BA deconjugation and biotransformation pathways have
been reconstructed in a resource of genome-scale reconstruc-
tions of >800 human gut microbes.49,50 Of these, only 23 species
could synthesize 3-dehydrochenodeoxycholic acid, only 4 could
synthesize LCA, and only 3 could synthesize UDCA.50 For
instance, the species Ruminococcus (Blautia) gnavus and
Collinsella aerofaciens synthesize 3-dehydroxychenodeoxycholic
and UDCA, Eggerthella lenta synthesizes 3-dehydrochenodeoxy-
cholic, and several Clostridiales representatives synthesize
LCA,50 indicating that these species may play a role in AD. Inter-
estingly, increased LCA in plasma has recently been proposed as
a potential biomarker for AD.51 Recent reports have shown the
influence of BAs in the host metabolism via alterations of the
bacterial community structure.52 The personalized brain models
developed in this study could be joined with the personalized
microbial community models established previously.50,53 In
future efforts, such combined host-microbe metabolic modeling
will yield more insight into mechanisms underlying altered BA
metabolism in AD.
Limitations of Study
Despite using three independent cohorts, transcriptomics data
are insufficient to fully parametrize the metabolic models. If
denser longitudinal omics data become available, then they will
help improve the predictions from these in silico models.
Although our analysis identifies reactions that are significant in
these conditions, the directionality of the reactions can only be
solidly determined if we have additional time-series metabolo-
mics data (and ideally, isotopic labeling experiments). Methods
are being developed to obtain cell-type-specific data54,55 from
which we can gain additional information regarding distinct
cell-type specific metabolic changes in AD. These studies
have shown that microglia and neuronal cells had different
transcriptional responses in AD versus control. Integrating
such cell-specific data will help in refining the models and
making more accurate predictions.
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Materials Availability
This study did not generate new unique reagents.
Data and Code Availability
The post-mortem brain transcriptome data used in this study can be downloaded from https://www.synapse.org/#!
Synapse:syn2580853. The targeted metabolomics data of bile acids used in this study can be downloaded from https://www.
synapse.org/#!Synapse:syn10235594. The code used for reconstruction and model generation and simulation are provided in
GitHub https://github.com/PriceLab/Bile_acid_AD
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Details of sample collection, description of post-mortem brain samples, RNA extraction, library preparation and sequencing are pro-
vided in previously published work.56–58 The combined samples from three independent cohorts consisted of 2114 post-mortem
samples (Table S1). There were 265 samples of temporal cortex (TC) and cerebellum (CER), 632 samples of frontal cortex (FC),
303 samples of frontal pole (FP), superior temporal gyrus (STG), inferior frontal gyrus (IFG) and parahippocampal gyrus (PHG) with
pathologies such as AD, MCI, Parkinson’s and control. Summary of sample sizes of AD cases and controls are shown in Table
S1 and represented in Figure 1. Details of sample collection, preparation, and metabolite quantification are provided in previously
published work.59 Sample details and quantified bile acids are provided in Table S2.
REAGENT or RESOURCE SOURCE IDENTIFIER
Biological Samples
Extracts of brain tissue Rush Alzheimer’s Disease Center
(RADC) Research Resource Sharing Hub
https://www.radc.rush.edu/
Extracts of brain tissue NIH Brain Tissue Repository, Ichan
School of Medicine at Mount Sinai
https://icahn.mssm.edu/research/nih-brain-
tissue-repository
Extracts of brain tissue Mayo Clinic Brain Bank https://www.brainsupportnetwork.org/brain-
donation/mayo-clinic/
Deposited Data
Post-mortem brain transcriptome data Synapse https://www.synapse.org/#!Synapse:syn2580853/
Metabolomics data Synapse https://www.synapse.org/#!Synapse:syn10235594/
Software and Algorithms
MATLAB R2018a MathWorks https://www.mathworks.com/products/matlab.html
COBRA toolbox v3.0 Heirendt et al.77 https://opencobra.github.io/cobratoolbox/stable/
Gurobi optimizer v7.5 Gurobi https://www.gurobi.com/academia/
IBM CPLEX v12.7.1 IBM https://www.ibm.com/analytics/cplex-optimizer
mCADRE algorithm Wang et al.63 http://bmcsystbiol.biomedcentral.com/articles/
10.1186/1752-0509-6-153
iMAT algorithm Zur et al.74 https://doi.org/10.1093/bioinformatics/btq602
TReNA package Bioconductor https://rdrr.io/bioc/TReNA/
Cytoscape 3.7.1 Cytoscape https://cytoscape.org/
Other
Codes for model generation and
simulation
GitHub https://github.com/PriceLab/Bile_acid_AD





Transcriptome analysis of post-mortem brain samples
Transcriptome data was obtained from post-mortem brain samples of AD patients and cognitively normal individuals from Religious
Orders Study and Memory and Aging Project (ROSMAP), Mayo Clinic, University of Florida, Institute for Systems Biology and Mount
Sinai Brain Bank (MSBB). 265 samples of temporal cortex (TC) and cerebellum (CER), 632 samples of frontal cortex (FC), 303 samples
of frontal pole (FP), superior temporal gyrus (STG), inferior frontal gyrus (IFG) and parahippocampal gyrus (PHG) with pathologies
such as AD, MCI, Parkinson’s and control were analyzed and used for construction of brain region-specific metabolic models.
ROSMAP data can be requested via the Rush Alzheimer’s Disease Center website (https://www.radc.rush.edu/). RNA-seq libraries
were prepared by different methods such as poly-A enriched, strand-specific and ribo-zero. The RNaseq data from different centers
were uniformly processed using a consensus set of tools as described in Logsdon et al.,60 with only library type-specific parameters
varying between pipelines. The authors performed library normalization using fixed/mixed effects modeling. To summarize the
method in Logsdon et al.60 for normalization, the genes were filtered and only those genes that had more than 1 CPM in 50% of sam-
ples were retained for analysis. Conditional quantile normalization was done to account for variations in gene length and GC content
and principal component analysis was used to detect sample outliers. Weighted linear models were used to estimate the confidence
of sampling abundance by using the voom-limma package in Bioconductor. This workflow was used to account for differences be-
tween the samples, experimental batch effects, and technical variations due to RNA-Seq. We have used these uniformly-processed
data for analysis in our study. Table S1 has information on the number of patients with various pathologies and controls andmethods
used for RNA-sequencing. The data used in the preparation of this article were downloaded from Synapse (https://www.synapse.
org/#!Synapse:syn2580853/). We performed two-tailed t test with Benjamini-Hochberg correction to identify differentially expressed
genes with corresponding p values. The differential expression analysis for transcriptome data from three independent cohorts is
presented in Table S1.
Bile acid sample preparation and analysis
Participants of the Religious Orders Study (ROS) are comprised of Catholic brothers, nuns, and priests who were cognitively normal
at study entry and agreed to annual clinical examinations and brain donation at time of death. The Rush Memory and Aging Project
(MAP) is a companion study that includes community-dwelling older adults that all agreed to evaluations similar to ROS. Quantifica-
tion of bile acid concentration was performed at the University of Hawaii cancer center. The bile acid-free matrix (BAFM) was used to
prepare bile acid calibrators. Extracts of brain tissue along with bile acid reference standards were subjected to instrumental anal-
ysis.61,62 All of the 57 bile acid standards were obtained from Steraloids Inc. (Newport, RI) and TRCChemicals (Toronto, ON, Canada)
and 9 stable isotope-labeled standards were obtained from C/D/N Isotopes Inc. (Quebec, Canada) and Steraloids Inc. (Newport, RI).
A Waters ACQUITY ultra performance LC system coupled with a Waters XEVO TQ-S mass spectrometer was used for all analyses.
Chromatographic separations were performedwith an ACQUITY BEHC18 column. UPLC-MS raw data obtainedwith negativemode
were analyzed using TargetLynx applications manager to obtain calibration equations and the quantitative concentration (mM) of
each bile acid. Bile acids were measured from the dorsolateral prefrontal cortex of 111 individuals with brain pathology (28, 33,
10, 22 and 18 with CERAD score of 1, 2, 3, 4 and 9 (missing), respectively). Metabolomics data can be accessed with permission
at https://www.synapse.org/#!Synapse:syn10235594. We calculated the ratio of primary and secondary bile acids measured in
metabolomics study and performed two-tailed t test to calculate p value for each bile acid.
Brain region-specific metabolic reconstruction
We used transcriptome data (https://www.synapse.org/#!Synapse:syn2580853/) derived from post-mortem brain samples of three
independent cohorts: Mayo clinic, ROSMAP and Mount Sinai Brain Bank. These cohorts contained information of different brain
regions (CER, FC, TC, FP, STG, IFG and PHG) and the data was used to generate brain region-specific metabolic networks. We con-
verted the transcriptome data to binary by considering transcripts with expression values less than 25th percentile in the matrix as
0 otherwise 1. We calculated ubiquity scores for genes in each brain region separately and used those for implementing mCADRE
workflow.63 The ubiquity score of a gene is equal to the sum of samples in which the gene is expressed divided by the total number of
samples. The Recon 3D model31 of human metabolism was used as template to reconstruct brain region-specific metabolic
networks as this model had information of reactions related to the primary and conjugated primary acids additionally added to refine
the model. The mCADRE workflow required two inputs to build region-specific metabolic models: (1) a global metabolic reconstruc-
tion, which in this case was the Recon 3D model, and (2) region-specific gene expression data from many individuals. Using the
mCADRE workflow, we generated the draft reconstructions for each brain region. We used functions in COBRA toolbox such as
detectDeadEnds to identify dead endmetabolites and identifyBlockedRxns to compute all blocked reactions in the draft reconstruc-
tions. We used reactions from the Recon 3D model for filling gaps in the metabolic network. We carried out this step for each
metabolic network reconstructed for brain regions. We also removed the reactions belonging to drug metabolism from the network
as they were not related to functions in the brain. Only the partial urea cycle is reported to be active in the brain, and so we identified
enzymes in the urea cycle that are present in the brain64 and included the reactions related to these genes in the metabolic networks.
We also included exchange reactions for metabolites identified in the cerebrospinal fluid (CSF) (by metabolomics data as well as the
whole-body metabolism reconstruction53 and metabolites that can be taken up across the blood brain barrier (BBB) from blood into




the CSF.65–70 The list of metabolites known to pass the BBB is provided in Table S12. Using the removeUnusedGenes function in the
COBRA toolbox we removed genes that were not used in any reaction in the reconstructions. Thenwe carried out manual curation for
genes present in the metabolic network using information from Human Protein Atlas71 for genes expressed in the brain. This effort
helped in providing further evidence for genes being present in the metabolic networks for brain regions. The information for reac-
tions, metabolites and genes inmetabolic networks of brain regions is provided in Tables S4–S10.We tested our models for 16meta-
bolic tasks (Table S11) that are brain specific and the models passed 65%–85% of those tests. As astrocytes are predominantly
involved inmaintaining brain physiology,72 we used objective function of astrocytes for our brainmetabolic networks.We constrained
bounds of exchange reactions using information from a published work on metabolic interactions between cell types in the brain.73
Details of metabolites involved in objective function and bounds for constrained reactions are given in Tables S4–S10. We integrated
expression data with the brain region-specific metabolic networks and generated context-specific personalized metabolic networks
for each sample in the study using iMAT algorithm.74 Flux variability analysis75 was carried out to evaluate minimum and maximum
flux for each reaction in the metabolic networks. The context-specific metabolic networks were sampled using Markov Chain Monte
Carlo (MCMC) sampling method as described in Bordbar et al.76 The sampling distribution for each reaction in the network was
considered as significantly different between AD and CN if the two distributions overlapped by less than 5%. Table S13 has the
results of sampling analysis. The codes used for reconstruction and model generation and simulation are provided in GitHub
(https://github.com/PriceLab/Bile_acid_AD). We used COBRA toolbox v3.077 for metabolic analysis that was implemented in
MATLABR2018a and academic licenses of Gurobi optimizer v7.5 and IBMCPLEX v12.7.1 were used to solve LP andMILP problems.
Reaction and pathway-level analysis
We carried out flux variability analysis75 for each context-specific personalized metabolic network and used the values for predicting
metabolic changes in AD versus CN individuals and sex of the individuals. FVA results were used to generate a matrix in which re-
actions for which bothminimum (vmin) andmaximum (vmax) FVA flux are 0, were considered to be non-active and assigned a state of
0, while the remaining reactions were assigned a state of 1. We carried out this analysis for all context-specific metabolic networks.
Thus, our matrix contained binary values for all reactions in 2114 context-specific personalized metabolic networks for seven brain
regions. We used this scheme to classify the reactions and obtain information not only on the basis of flux measurements but also
their activity in each network. From all the reactions in the metabolic networks, we selected only those that belonged to cholesterol
metabolism, bile acid synthesis and transport reactions associated with the bile acid metabolites. We applied Fisher’s exact test on
the binarized values of reactions to identify those reactions with p value < 0.05 in AD versus CN. These reactions were identified as
significant reactions in these groups.
Metabolic regulatory network
The transcriptional regulatory network analysis (TReNA) package (https://rdrr.io/bioc/TReNA/) was used for identifying transcription
factors (TFs) that are part of the co-expression modules of interest. Brain-specific transcriptional regulatory network was con-
structed78 using information from ENCODE. We downloaded the DNase Hypersensitivity (DHS) fastq files from ENCODE for all avail-
able brain samples and aligned the sequences using the SNAP method.79 We performed two alignments using seed size of 16 and
20bp. The length of sequence data was > 50 bp. The regions of open chromatin were identified using peak calling algorithm, F-Seq.80
Footprints were generated using default parameters for Wellington81 and HINT.82 Our method generated individual genemodels and
those footprints that are within the proximal promoter region (+/5 kb of the transcription start site) are considered as priors in as-
sessing the relationship between the expression of the TF and target genes. We prioritized putative TF regulators for each gene in the
model using LASSO regression techniques, Pearson andSpearman correlation and random forest methods and projected the scores
from these approaches into PCA space. The principal components were summed together to obtain a single composite score called
pcaMax. This process is part of the trena package in Bioconductor (https://rdrr.io/bioc/TReNA/) and we applied the method to the
post-mortem samples from the temporal cortex from Mayo Clinic. We used metabolic genes identified from reaction-level analysis
involved in bile acid and cholesterol metabolism and mapped top five transcription factors that interact with these metabolic genes
and created an interaction network. These interaction networks gave information for transcription factors that regulate metabolic
genes and are involved in significant reactions in AD versus cognitively normal individuals. Cytoscape 3.7.183 was used for visualizing
the brain transcriptional regulatory network.
QUANTIFICATION AND STATISTICAL ANALYSIS
For DEG analysis, two-tailed t test with Benjamini-Hochberg correction was used for comparison between AD and CN samples. For
targeted metabolomics data, we used the ratio of primary and secondary bile acids and performed two-tailed t test to calculate
p values. Fisher’s exact test was used on the binarized values of reactions and p value was calculated. A p value of < 0.05 is consid-
ered statistically significant. We used LASSO regression, Pearson and Spearman correlation and random forest for calculating
scores for putative TF regulators for each gene in the model,
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